Trial medication for primary immune thrombocytopenia

Are you:

• a healthy male 
• aged from 18 to 50 years (inclusive)
• with a BMI from 18,0 to 30,0 kg/m² (inclusive)
• non-smoker, (including e-cigarettes) or ex-smoker
• not using daily medication

What does the trial involve?

SGS study BE-80-2100607  investigates the treatment of primary immune thrombocytopenia. 
During 18 weeks you will have the following appointments

• a screening 
• 2 periods of a 5-day (4-night) stay 
• 14 to 15 short follow-up visits per period 
• a final examination

Take part in this trial and:

• help us develop tomorrow's medicines
• and receive a generous tax-free (in Belgium) payment of € 5300

View information leaflet